从诱导多能干细胞中产生悬浮液中的肾脏类器官
September 1st, 2023
该方案提供了一种使用悬浮培养条件从诱导多能干细胞（iPSC）生产肾脏类器官的全面有效的方法。本研究的主要重点在于确定初始细胞密度和 WNT 激动剂浓度，从而使对肾脏类器官研究感兴趣的研究人员受益。
我们的研究提出了一种全面有效的方法，利用悬浮培养条件从诱导多能干细胞生产肾脏类器官。我们强调诱导阶段初始细胞密度和 WNT 激动剂浓度的重要性，这将培养新的类器官研究人员。目前，很难获得单一的高密度iPSC细胞系。
批次影响是显而易见的，特别是在各种iPSC细胞系中。每批的肾脏类器官可能具有不同的形状和大小。需要多次尝试才能获得一个 iPSC 细胞系的最佳初始细胞密度和 CHIR 浓度。
我们已经确定，中间方法的初始分化对于肾脏类器官的成功形成很重要。我们的方案详细描述了如何在过程中选择最佳细胞密度和CHIR浓度，因为不同的iPSC细胞系显示出细胞增殖和分化能力的差异。研究人员可以从他们的iPSC中快速生成特定的肾脏类器官。
根据我们的方案，通过调整细胞密度和CHIR浓度，毫无疑问，我们所有的研究人员都专注于他们的肾脏疾病。我们实验室未来的研究必须优化疾病模型中的方案方法，再生新药和药物筛选。近五年来，本实验室将基于患者发育、iPSC和肾脏组织疾病模型，专注于各种遗传性肾病的表观遗传学和细胞专题药物开发。
View the full transcript and gain access to thousands of scientific videos
概述
该协议介绍了一种使用悬浮培养条件从诱导多能干细胞（iPSCs）生产肾脏类器官的全面而有效的方法。该研究强调了初始细胞密度和WNT激动剂浓度的重要性，为肾脏类器官研究的研究人员提供了宝贵的见解。
关键研究组成部分
科学领域
- 神经科学
- 干细胞生物学
- 类器官研究
背景
- 肾脏类器官对于研究肾脏发育和疾病至关重要。
- 诱导多能干细胞（iPSCs）为类器官生成提供了一个有前景的来源。
- 在实现iPSCs的一致高密度细胞系方面存在挑战。
- 不同iPSC批次之间可能会出现类器官形态和大小的变异。
研究目的
- 建立从iPSCs生成肾脏类器官的可靠方法。
- 确定最佳的初始细胞密度和WNT激动剂浓度。
- 协助类器官技术领域的新研究人员。
使用的方法
- 用于类器官形成的悬浮培养条件。
- 初始细胞密度和WNT激动剂浓度的评估。
- 不同iPSC系之间类器官特征的比较。
- 迭代优化培养条件以获得最佳结果。
主要结果
- 初始细胞密度显著影响类器官的发育。
- WNT激动剂浓度对于成功的类器官形成至关重要。
- 在不同iPSC系之间观察到类器官形态的变异。
- 可能需要多次尝试才能达到最佳条件。
结论
- 该研究为肾脏类器官的生成提供了一个有价值的协议。
- 理解细胞密度和WNT浓度的作用至关重要。
- 这项研究将有助于推进肾脏类器官研究。
常见问题
Executive Industry Relevance
Suspension-based generation of kidney organoids from iPSCs enables scalable, reproducible disease models for early-stage drug discovery and nephrotoxicity screening. Optimizing initial cell density and WNT agonist concentration directly impacts the predictive confidence and standardization of organoid-based assays. This protocol supports translational research continuity and portfolio-wide risk reduction in renal target validation and compound evaluation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of renal developmental pathways and disease mechanisms in a controlled 3D system.
- Supports functional target validation by recapitulating nephron structures from diverse iPSC lines.
- Facilitates mechanistic de-risking through reproducible differentiation and organoid formation.
Screening & Assay Development
- Provides standardized, animal component-free organoids for compound screening and nephrotoxicity assessment.
- Delivers quantitative, reproducible outputs by controlling cell density and WNT agonist exposure.
- Enables scalability and platform reuse across multiple iPSC lines and disease models.
Translational & Preclinical Research
- Aligns with disease-relevant modeling for hereditary kidney disorders using patient-derived iPSCs.
- Supports continuity from discovery through preclinical validation by enabling drug response studies in organoids.
- Reduces translational risk by providing human-relevant nephron structures for biomarker and efficacy studies.
Pipeline & Workflow Integration
This protocol integrates into the discovery-to-preclinical continuum, supporting early target validation, lead identification, and translational research in renal biology.
- Discovery Biology: Facilitates hypothesis testing and pathway clarification in kidney development and disease.
- Screening: Delivers assay-ready, reproducible organoids for compound evaluation and toxicity profiling.
- Analytics: Provides quantitative readouts of nephron structure formation and functional uptake (e.g., dextran in proximal tubules).
- Translational Research: Enables disease modeling and drug response studies in patient-specific organoids.
- Enterprise Reuse: Offers a standardized, adaptable protocol for diverse iPSC lines and renal disease models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in renal target validation.
- Operational Value: Enhances reproducibility and scalability through defined, animal-free culture conditions.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling robust, human-relevant assays.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of renal drug candidates.
Implementation Considerations
- Requires expertise in iPSC culture, differentiation, and organoid handling.
- Needs access to low-adhesion plates, orbital shakers, and quantitative imaging or functional assays.
- Demands cross-team standardization of cell density and WNT agonist concentration for reproducibility.
- Must be adapted for variability across iPSC lines and disease-specific models.
- Batch-to-batch variability in organoid morphology and size requires iterative optimization.
